pmc logo image
Logo of annrheumdAnnals of the Rheumatic DiseasesCurrent TOCInstructions for authors
Journal List > Ann Rheum Dis > v.61(7); Jul 2002

Formats:
Ann Rheum Dis. 2002 July; 61(7): 608–611.
doi: 10.1136/ard.61.7.608.
PMCID: PMC1754144
Copyright notice
Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis
T Avcin, R Cimaz, F Falcini, F Zulian, G Martini, G Simonini, V Porenta-Besic, G Cecchini, M Borghi, and P Meroni
Department of Paediatrics, University of Ljubljana, Slovenia, Italy.
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
Background: Antibodies against cyclic citrullinated peptide (anti-CCP) are considered to be specific for rheumatoid arthritis (RA).
Objective: To assess the clinical significance of anti-CCP in a cohort of patients with juvenile idiopathic arthritis (JIA).
Methods: Anti-CCP were tested by an enzyme linked immunosorbent assay (ELISA) in serum samples from 109 patients with JIA (30 boys, 79 girls), with a mean age of 8.7 years (range 0.6–20.3) and mean disease duration of 3.6 years (range 3 months to 15.6 years). As control groups, anti-CCP were also tested in sera of 30 healthy children, 25 patients with juvenile onset systemic lupus erythematosus (SLE), and 50 adult patients (30 with RA, 20 with SLE).
Results: Positive anti-CCP values were found in sera of two patients with JIA (2%), one with polyarthritis, and one with oligoarthritis. Statistical analysis showed that anti-CCP were not associated with the presence of antinuclear antibodies, raised erythrocyte sedimentation rate, or erosions. In the control groups, none of the patients with juvenile onset SLE and only one of 20 adults with SLE were positive for anti-CCP, but 19/30 (63%) adults with RA showed anti-CCP positivity.
Conclusions: Anti-CCP can be detected in children with JIA, but are less frequently present than in adults with RA.
Full Text
The Full Text of this article is available as a PDF (117K).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Vincent C, de Keyser F, Masson-Bessière C, Sebbag M, Veys EM, Serre G. Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis. 1999 Jan;58(1):42–48. [PubMed]
  • Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Ménard HA, Zhou ZJ, Palosuo T, Van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR, Jr, El-Gabalawy HS. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000;2(3):236–243. [PubMed]
  • Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000 Jan;43(1):155–163. [PubMed]
  • Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ, Serre G. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995 Jun;95(6):2672–2679. [PubMed]
  • Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998 Jan 1;101(1):273–281. [PubMed]
  • Simon M, Girbal E, Sebbag M, Gomès-Daudrix V, Vincent C, Salama G, Serre G. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest. 1993 Sep;92(3):1387–1393. [PubMed]
  • Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessière C, Jolivet-Reynaud C, Jolivet M, Serre G. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol. 1999 Jan 1;162(1):585–594. [PubMed]
  • Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998 Mar 28;351(9107):969–973. [PubMed]
  • Lawrence JM, 3rd, Moore TL, Osborn TG, Nesher G, Madson KL, Kinsella MB. Autoantibody studies in juvenile rheumatoid arthritis. Semin Arthritis Rheum. 1993 Feb;22(4):265–274. [PubMed]
  • Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol. 1996 Nov;23(11):1975–1980. [PubMed]
  • Gedalia A, Molina JF, García CO, Doggett S, Espinoza LR, Gharavi AE. Anticardiolipin antibodies in childhood rheumatic disorders. Lupus. 1998;7(8):551–553. [PubMed]
  • Serra CR, Rodrigues SH, Silva NP, Sztajnbok FR, Andrade LE. Clinical significance of anticardiolipin antibodies in juvenile idiopathic arthritis. Clin Exp Rheumatol. 1999 May–Jun;17(3):375–380. [PubMed]
  • Avcin T, Ambrozic A, Bozic B, Accetto M, Kveder T, Rozman' B. Estimation of anticardiolipin antibodies, anti-beta2 glycoprotein I antibodies and lupus anticoagulant in a prospective longitudinal study of children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002 Jan–Feb;20(1):101–108. [PubMed]
  • Nesher G, Moore TL, Grisanti MW, el-Najdawi E, Osborn TG. Antiperinuclear factor in juvenile rheumatoid arthritis. Ann Rheum Dis. 1992 Mar;51(3):350–352. [PubMed]
  • Gabay C, Prieur AM, Meyer O. Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. Ann Rheum Dis. 1993 Nov;52(11):785–789. [PubMed]
  • el-Gamal Y, Hossny E, Mabrouk R, el-Gamasey T. Antiperinuclear factor in the diagnosis of juvenile rheumatoid arthritis. Pediatr Allergy Immunol. 1995 Aug;6(3):165–169. [PubMed]
  • Serra CR, Rodrigues SH, Sztajnbok FR, Silva NP, Andrade LE. Antiperinuclear factor and antibodies to the stratum corneum of rat esophagus in juvenile idiopathic arthritis. J Pediatr. 1999 Apr;134(4):507–509. [PubMed]
  • Abreu I, Gomes JA. "Antikeratin antibodies" in chronic arthritis of childhood. Clin Exp Rheumatol. 1998 Jul–Aug;16(4):516–517. [PubMed]
  • Hromadníková I, Vavrincova P, Stechova K, Hridelova D. Anti-keratin antibodies in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2001 Jul–Aug;19(4):470–473. [PubMed]
  • Osborn TG, Patel NJ, Moore TI, Zuckner J. Use of the HEp-2 cell substrate in the detection of antinuclear antibodies in juvenile rheumatoid arthritis. Arthritis Rheum. 1984 Nov;27(11):1286–1289. [PubMed]
  • Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997 Sep;40(9):1601–1611. [PubMed]
  • Nicoletti F, Borghi MO, Barcellini W, Fain C, Beltrami B, Del Papa N, Schorlemmer HU, Mottola L, Meroni PL. Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. Eur J Pharmacol. 1996 Sep 12;311(2-3):213–220. [PubMed]
  • Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem. 2001 Jun;47(6):1089–1093. [PubMed]
  • van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, Gmelig-Meyling FH, van Booma-Frankfort C, de Jong BA, van Venrooij WJ, Bijlsma JW. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol. 1999 Nov–Dec;17(6):689–697. [PubMed]
  • Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000 Aug;43(8):1831–1835. [PubMed]
  • Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 2001 Jan;60(1):67–68. [PubMed]
  • Nesher G, Wilson VK, Moore TL, Osborn TG, Hanna VE. Antiperinuclear and anti-RA33 antibodies in juvenile chronic arthritis. Ann Rheum Dis. 1994 Apr;53(4):282–283. [PubMed]
  • Berthelot JM. Antiperinuclear factor in the polyarticular form of juvenile chronic arthritis: are use of frozen material or age of patients relevant? Ann Rheum Dis. 1995 Jan;54(1):76–77. [PubMed]
  • Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, Breedveld FC, Verweij CL. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum. 2001 Jan;44(1):41–47. [PubMed]
  • Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol. 2001 Mar 15;166(6):4177–4184. [PubMed]
Figures and Tables
Figure 1
Figure 1
Figure 1
The cumulative results of anti-CCP assays in all the patients studied. Serum values of anti-CCP are shown in the group of patients with juvenile idiopathic arthritis (JIA), healthy children, patients with juvenile onset systemic lupus erythematosus (JSLE), (more ...)
Figure 2
Figure 2
Figure 2
Anti-CCP values in patients with different subtypes of JIA (polyarticular, oligoarticular, and systemic disease). The horizontal lines indicate means of pooled data for each subtype of JIA. The cut off value is indicated as a horizontal dashed line.
Articles from Annals of the Rheumatic Diseases are provided here courtesy of
BMJ Group

PubMed articles by these authors